文献速递食管胃疾病与幽门螺杆菌

既往大环内酯类抗生素暴露对幽门螺杆菌感染治疗效果的影响

Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes.
PubMed 文献 · Am J Gastroenterol · 2019-01-01

基于Clalit健康服务数据库2010至2015年首次接受C-尿素呼气试验的25-60岁人群,共纳入7842例,其中3062例(39.0%)有大环内酯类暴露史。含克拉霉素三联疗法(TT-C)在大环内酯暴露者中疗效为74.3%,无暴露者为82.4%(OR 0.62;95%CI 0.55-0.70;P<0.0001)。序贯疗法和伴同疗法疗效分别为82.7%和81.3%,未受大环内酯暴露显著影响。

要点

  • 既往大环内酯暴露降低含克拉霉素三联疗法根除率:暴露者74.3% vs 无暴露者82.4%(OR 0.62;95%CI 0.55-0.70;P<0.0001)。
  • 克拉霉素、罗红霉素、红霉素暴露均与TT-C成功根除呈负相关,阿奇霉素暴露未见显著影响。
  • 序贯疗法(82.7%)和伴同疗法(81.3%)疗效未受大环内酯暴露显著影响。

核心结论

  • 含克拉霉素三联疗法受既往大环内酯类抗生素暴露的不良影响。
  • 在此情况下,序贯疗法、伴同疗法和含铋方案可能更受优选(作者结论)。

研究设计与样本

  • 检索Clalit健康服务数据库,纳入2010至2015年间首次接受C-尿素呼气试验的25-60岁受试者。
  • 排除既往接受过幽门螺杆菌粪便抗原检测或胃镜检查的患者,并检索药房配药数据。
  • 共纳入7842例受试者(男性36.1%,年龄40.3±10.5岁),其中3062例(39.0%)有既往大环内酯暴露史。

主要发现

  • 含克拉霉素三联疗法在有大环内酯暴露者中疗效为74.3%,无暴露者为82.4%(OR 0.62;95%CI 0.55-0.70;P<0.0001)。
  • TT-C成功根除受克拉霉素暴露(55.5%;OR 0.31;95%CI 0.24-0.39;P<0.0001)、罗红霉素暴露(74.4%;OR 0.65;95%CI 0.58-0.74;P<0.0001)和红霉素暴露(73.9%;OR 0.72;95%CI 0.57-0.89;P<0.01)的不良影响,但阿奇霉素暴露未见显著影响。
  • 距克拉霉素和罗红霉素暴露的时间越长,根除率越高(OR 1.007;95%CI 1.002-1.012;P<0.01 和 OR 1.004;95%CI 1.002-1.006;P<0.0001)。
  • 克拉霉素和罗红霉素剂量越高,成功根除的可能性越低(OR 0.99988;95%CI 0.99982-0.99996;P<0.01 和 OR 0.99981;95%CI 0.99971-0.99992;P<0.001)。
  • 序贯疗法和伴同疗法的疗效分别为82.7%和81.3%,未受大环内酯暴露显著影响。

临床怎么用

  • 作者结论认为,含克拉霉素三联疗法受既往大环内酯类抗生素暴露的不良影响。
  • 作者结论认为,在此情况下序贯疗法、伴同疗法和含铋方案可能更受优选。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Helicobacter pylori (H. pylori) guidelines, including the recent ACG clinical guideline, recommend avoiding clarithromycin-based triple therapy (TT-C) among patients with past macrolide exposure. Data to support this recommendation are scarce, and the impact of macrolide exposure on quadruple therapies is unclear. We aimed to determine the impact of macrolide exposure on the efficacy of H. pylori treatment in our region. METHODS: We searched the Clalit Health Services database to identify subjects aged 25-60 years who underwent the first-ever C-urea breath test between 2010 and 2015. Patients who underwent a previous H. pylori stool antigen test or gastroscopy were excluded. Pharmacy dispensation data were retrieved. RESULTS: We identified 7,842 subjects (36.1% male individuals, age: 40.3 ± 10.5 years), including 3,062 (39.0%) with previous macrolide exposure. The efficacy of TT-C was 74.3% and 82.4% among subjects with and without macrolide exposure, respectively (odds ratio (OR), 0.62; 95% confidence interval (CI), 0.55-0.70; P < 0.0001). TT success was adversely affected by exposure to clarithromycin (55.5%; OR, 0.31; 95% CI, 0.24-0.39; P < 0.0001), roxythromycin (74.4%; OR, 0.65; 95% CI, 0.58-0.74; P < 0.0001), and erythromycin (73.9%; OR, 0.72; 95% CI, 0.57-0.89; P < 0.01) but not by exposure to azithromycin. A greater time elapsed because exposure to clarithromycin and roxythromycin was associated with higher eradication (OR, 1.007; 95% CI, 1.002-1.012; P < 0.01 and OR, 1.004; 95% CI, 1.002-1.006; P < 0.0001). A higher dose of clarithromycin and roxythromycin was associated with a lower likelihood of successful eradication (OR, 0.99988; 95% CI, 0.99982-0.99996; P < 0.01 and OR, 0.99981; 95% CI, 0.99971-0.99992; P < 0.001). The efficacies of sequential and concomitant therapies were 82.7% and 81.3%, respectively, and were not significantly affected by macrolide exposure. CONCLUSIONS: TT-C is adversely affected by previous exposure to macrolide antibiotics. Sequential, concomitant, and bismuth-based treatment may be preferred in this setting.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Boltin D, Levi Z, Gingold-Belfer R, et al. Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes. Am J Gastroenterol. 2019. PMID: 31095531. doi:10.14309/ajg.0000000000000223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。